Barclays PLC’s $2 Billion in Healthcare Sector Stock Positions: PFE, LLY, BMY, UNH, MRK, TEVA

Wall St. Watchdog reveals information regarding Barclays PLC’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 807 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $2.055 billion.

  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Barclays PLC reported holding 19,879,991 shares with a market value of $409,527,822. This comprised 1.06% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 21,797,402 shares with a market value of $385,378,074. This comprised 1.36% of the total portfolio. The net change in shares for this position over the two quarters is 1,917,411. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, Barclays PLC reported holding 2,731,978 shares with a market value of $102,531,131. This comprised 0.26% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 6,776,633 shares with a market value of $250,532,130. This comprised 0.88% of the total portfolio. The net change in shares for this position over the two quarters is 4,044,655. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Barclays PLC reported holding 1,997,111 shares with a market value of $132,847,817. This comprised 0.34% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 2,115,268 shares with a market value of $134,721,416. This comprised 0.48% of the total portfolio. The net change in shares for this position over the two quarters is 118,157. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Barclays PLC reported holding 11,170,518 shares with a market value of $323,498,191. This comprised 0.84% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 3,075,656 shares with a market value of $96,514,083. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is -8,094,862. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Barclays PLC reported holding 1,445,314 shares with a market value of $74,549,299. This comprised 0.19% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 1,752,986 shares with a market value of $80,847,712. This comprised 0.29% of the total portfolio. The net change in shares for this position over the two quarters is 307,672. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, Barclays PLC reported holding 1,252,614 shares with a market value of $73,090,025. This comprised 0.19% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 1,257,704 shares with a market value of $69,123,411. This comprised 0.24% of the total portfolio. The net change in shares for this position over the two quarters is 5,090. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Barclays PLC reported holding 2,706,401 shares with a market value of $95,508,894. This comprised 0.25% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 2,107,534 shares with a market value of $68,916,363. This comprised 0.24% of the total portfolio. The net change in shares for this position over the two quarters is -598,867. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): On 06/30/2011, Barclays PLC reported holding 2,072,888 shares with a market value of $99,954,662. This comprised 0.26% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 1,815,118 shares with a market value of $67,558,694. This comprised 0.24% of the total portfolio. The net change in shares for this position over the two quarters is -257,770. About Company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.
  • Cephalon Inc. (NASDAQ:CEPH): On 06/30/2011, Barclays PLC reported holding 1,567,078 shares with a market value of $125,209,535. This comprised 0.32% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 804,305 shares with a market value of $64,907,411. This comprised 0.23% of the total portfolio. The net change in shares for this position over the two quarters is -762,773. About Company: Cephalon, Inc. is an international biopharmaceutical company that discovers, develops, and markets biopharmaceutical products to treat neurological disorders, pain, and cancer. The Company’s products include a product that treats excessive daytime sleepiness associated with narcolepsy.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Barclays PLC reported holding 1,876,290 shares with a market value of $98,730,378. This comprised 0.26% of the total portfolio. On 09/30/2011, Barclays PLC reported holding 1,214,482 shares with a market value of $62,108,609. This comprised 0.22% of the total portfolio. The net change in shares for this position over the two quarters is -661,808. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.

(Note: Data regarding Barclays PLC’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet